TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05660811
Drug: 6 months treatment with a single antiplatelet agent
Normalized name: Detoxifying agents for antineoplastic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuing single antiplatelet agent up until 6 months
Study: NCT05786638
Drug: Allergen Immunotherapy Extract
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual subcutaneous allergen immunotherapy
Study: NCT04819204
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
Study: NCT05197179
Drug: FB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Study: NCT00610337
Drug: Cethrin® (BA-210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative epidural administration during spinal decompression surgery
Study: NCT05143099
Drug: TEC
Normalized name: Ultec
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
Study: NCT05813522
Drug: Furmonertinib Mesilate Tablets
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
Study: NCT04526132
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours.
Study: NCT06485947
Drug: chemotherapy treatment called GPOH
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy treatment called GPOH
Study: NCT06018506
Drug: BR108 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Study: NCT04737889
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Study: NCT06719570
Drug: MK-8591A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination tablet
Study: NCT06719570
Drug: Doravine
Normalized name: doravine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05590117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets
Study: NCT05590117
Drug: FOLFOX-6 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of FOLFOX-6 regimen
Study: NCT06556277
Drug: Metyrapone And Hydrocortisone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7
Study: NCT06556277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7
Study: NCT04978584
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04978584
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06261567
Drug: Biologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
Study: NCT05207722
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
Study: NCT06237465
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
Study: NCT05487300
Drug: Autonomic testing on and off levodopa
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa.
Study: NCT06470373
Drug: Eylea® Solution for intravitreal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Study: NCT06277154
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially approved for cancer treatment
Study: NCT06039566
Drug: IV N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
Study: NCT06039566
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
Study: NCT05636306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Study: NCT05057819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
Study: NCT06081959
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on day 1 and Day 15 of each 28 day cycle
Study: NCT06081959
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
Study: NCT05691959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to placebo group will receive Normal Saline 50ml IV.
Study: NCT05983939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple ascending oral doses of matching placebo tablets.
Study: NCT05691959
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
Study: NCT05436678
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib
Study: NCT06213363
Drug: TCR1672 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
Study: NCT05764746
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
Study: NCT04785261
Drug: TCM Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
Study: NCT06190249
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV.
Study: NCT05459974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill once daily for 30 days after the atrial fibrillation ablation
Study: NCT06439524
Drug: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
Study: NCT06263517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
Study: NCT06648720
Drug: DAPT de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
Study: NCT06618521
Drug: Anti-hypertensive drug (Methyldopa 250 mg)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.
Study: NCT05351788
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Study: NCT05351788
Drug: KL-A167
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Study: NCT05333835
Drug: HR17031 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR17031 injection
Study: NCT05333835
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS068 injection
Study: NCT05333835
Drug: SHR20004 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004 injection
Study: NCT05512598
Drug: HB0034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0034, a single dose
Study: NCT06361212
Drug: Ethoximod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethoximod is a S1P1 modulator.
Study: NCT06618573
Drug: Isoniazid/Pyridoxine
Normalized name: ISONIAZID/PYRIDOXINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group received isoniazid 300mg and pyridoxine 10mg/day
Study: NCT06618573
Drug: Saccharum Lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received placebo
Study: NCT04990037
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04932083
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added.
Study: NCT06700395
Drug: TQB2029 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
Study: NCT06720896
Drug: APT-001 topical ophthalmic ointment (spinosad)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APT-001 topical ophthalmic ointment, administered once daily
Study: NCT06720896
Drug: Vehicle control for APT-001 topical ophthalmic ointment
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
Study: NCT05095077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to active IMP
Study: NCT04800263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected subcutaneously
Study: NCT04788953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects will receive placebo tablets for oral use.
Study: NCT06260059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To patients randomized to the placebo group, a placebo pill will be given
Study: NCT05507658
Drug: Tislelizumab combined with Oxaliplatin and Capecitabine
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles.
Study: NCT05238337
Drug: [14C]-PBI-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-radio-labeled-PBI-200
Study: NCT06383702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Study: NCT06445075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo will be administered every 4 weeks by intravenous (IV) infusion.
Study: NCT05633407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Study: NCT03949478
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
Study: NCT04967014
Drug: HIP2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04967014
Drug: RLD2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT05842785
Drug: Phase II-HNSCC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT05842785
Drug: Phase II-Advanced melanoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT05842785
Drug: Phase II-solid tumors or lymphomas
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT05177029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
Study: NCT05486988
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors
Study: NCT05486988
Drug: Chemotherapeutic Agent
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles
Study: NCT05486988
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4\~6 cycles
Study: NCT05470075
Drug: HR18042 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT05470075
Drug: HR18042 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT05470075
Drug: HR18042 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT05470075
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT05955885
Drug: Flurbiprofen Oral Lozenge
Normalized name: flurbiprofen Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
Study: NCT05955885
Drug: Flurbiprofen 8.75 MG
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
Study: NCT01861834
Drug: Omegaven 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN
Study: NCT04898712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
Study: NCT04810104
Drug: AZD0328
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study drug
Study: NCT04810104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug
Study: NCT05285592
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Treatment
Study: NCT06158009
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05428215
Drug: 17beta Estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
Study: NCT06481852
Drug: MTT with antibiotic preconditioning + placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study: NCT06537050
Drug: JX2105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06537050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05699603
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Applied topically
Study: NCT06721247
Drug: ICS+LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily
Study: NCT04783389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT05217758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, 7 days